- Home
- GHRS vs ORIC Comparison
GHRS vs ORIC Comparison
Compare GHRS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | ORIC |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 837.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GHRS | ORIC |
|---|---|---|
| Price | $21.47 | $8.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $41.38 | $19.73 |
| AVG Volume (30 Days) | 255.6K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.52 | $4.65 |
| 52 Week High | $24.66 | $14.93 |
Technical Indicators
Market Signals| Indicator | GHRS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 36.28 |
| Support Level | $12.29 | $7.90 |
| Resistance Level | $24.66 | $11.22 |
| Average True Range (ATR) | 1.26 | 0.53 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 67.11 | 2.37 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.